Amo Pharma Limited
Clinical trials sponsored by Amo Pharma Limited, explained in plain language.
-
New drug trial aims to ease symptoms of rare muscle disease in kids
Disease control CompletedThis study tested a drug called tideglusib against a placebo in 56 children aged 6 to 16 with congenital myotonic dystrophy, a rare genetic muscle condition. The goal was to see if tideglusib could reduce symptoms like muscle weakness and breathing problems. The trial was complet…
Phase: PHASE2, PHASE3 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis study tested a drug called tideglusib in 16 people aged 12 to 45 with a rare muscle disease called myotonic dystrophy type 1. The goal was to see if the drug is safe and how it works in the body. Participants took either 400 mg or 1000 mg of tideglusib, and researchers monit…
Phase: PHASE2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC